Onkologie. 2012:6(1):9-11

Bone cancer pain and possibilities of its treatment

Lukáš Pochop
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

Pain caused by bone involvement by tumor is the most common type of cancer pain. The management consists in the combination of pharmacotherapy

a non–pharmacological approaches. The mainstay of pharmacotherapy are NSAID, opioids, bisphosphonates, corticosteroids,

anticonulsants and antidepressants. We use also the radiotherapy, radionuclids and some orthopedic and radiologic interventions.

Keywords: bone cancer pain, non-opioids, opioids, radionuclids, radiotherapy

Published: February 29, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pochop L. Bone cancer pain and possibilities of its treatment. Onkologie. 2012;6(1):9-11.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61-66. Go to original source... Go to PubMed...
    2. Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001; 42(6): 895-906. Go to PubMed...
    3. Caraceni, A, Zecca, E, Bonezzi, C, Arcuri, E, Yaya Tur, R, Maltoni, M, Visentin M, Gorni G, Martini C, Tirelli W, Barbieri M, De Conno F. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004; 22: 2909-2917. Go to original source... Go to PubMed...
    4. Body JJ, Stopeck A, Fujiwara Y, Lipton A, Steger G, Viniegra M, Fan M, Dansey R, Susie J, Ada B. Results of a prospective, randomized, double-blind, double-dummy, Phase 3 study comparing denosumab with zoledronic acid for the treatment of breast cancer patients with bone metastases. Bone 2010; 46: S36-S37. Go to original source...
    5. Wu JS, Wong R, Johnston M, Bezjak A, Whelan T. Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003; 55: 594-605. Go to original source... Go to PubMed...
    6. Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone pain: Single fraction versus multifraction radiotherapy - A systematic review of randomized trials. Clin Oncol (R Coll Radiol) 2003; 15: 345-352. Go to original source... Go to PubMed...
    7. Chow E, Harris K, Fan G, Tsao MN, Sze WM. Palliative radiotherapy trials for bone metastases: A systematic review. J Clin Oncol 2007; 25: 1423-1436. Go to original source... Go to PubMed...
    8. Paes FM, Ernani V, Hosein P, Serafini AN. Radiopharmaceuticals: When and how to use them to treat metastatic bone pain. Supportive oncology 2011; 9(6): 197-205. Go to original source... Go to PubMed...
    9. Gkialas I, Iordanidou L, Galanakis I, et al. The use of radioisotopes for palliation of metastatic bone pain. J BUON 2008; 13(2): 177-183. Go to PubMed...
    10. Zafeirakis A. Can response to paliative treatment with radiopharmaceuticals be further enhanced? Hell J Nucl Med 2009; 12(2): 151-157.
    11. Sciuto R, Tofani A, Festa A, et al. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy. Clin Ther 1998; 149(921): 43-47.
    12. Storto G, Klain M, Paone G, et al. Combined therapy of Sr89 and zoledronic acid i in patients with painful bone metastases. Bone 2006; 39(1): 35-41. Go to original source... Go to PubMed...
    13. Doležal T, Hakl M, Kozák J, Kršiak M, Lejčko J, Skála B, Sláma O, Ševčík P, Vorlíček J. Metodické pokyny pro farmakoterapii bolesti. Bolest 2009; 12(Suppl. 2): 4-27.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.